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103 PREDICTIVE RELATIONSHIP OF SERUM MARKERS OF
CARTILAGE METABOLISM TO IMAGING AND CLINICAL
OUTCOME MEASURES OF JOINT INTEGRITY
P.A. Berry1, R.A. Maciewicz2, A.E. Wluka1, M.D. Downey-Jones2,
E.A. Mills2, C.J. Oakley2, F.M. Cicuttini1. 1Monash University,
Melbourne, AUSTRALIA, 2AstraZeneca, Macclesﬁeld, UNITED
KINGDOM
Purpose: Osteoarthritis (OA) is a heterogenous disease with outcomes
of pain and joint disability and often results in joint replacement, and is
on the incline due to an aging population and the adiposity epidemic.
This personal, societal and economic burden could be reduced with
better predictors of disease progression. This study aimed to examine
whether serum markers of cartilage metabolism provide a consistent
prediction model for change in cartilage quantity and integrity, and to
determine whether these markers relate to knee joint replacement, a
clinically relevant outcome.
Methods: Change in cartilage volume and defects over 2 years were
measured in a convenience group of 117 subjects with symptomatic and
radiographic knee OA using MRI. At 4-year follow-up, subjects were asked
whether they had undergone knee joint replacement. The relationships
between these cartilage changes, and odds of knee joint replacement with
baseline levels of serum markers of cartilage metabolism (N-propeptide
of type IIa procollagen (PIIANP), type II collagen breakdown product
(C2C), cartilage oligomeric matrix protein (COMP)) individually, and as
a ratio (PIIANP:C2C), were examined using multiple regression analysis
adjusted for age, gender and BMI.
Results: Higher level of PIIANP was associated with reduced medial
cartilage volume loss (p = 0.05) and reduced odds of knee joint replace-
ment at 4 years (p = 0.04) after adjustment for potential confounders.
Similar results were obtained when the ratio of PIIANP (synthesis) to
C2C (degradation) were considered i.e.. Higher levels of COMP were
associated with reduced medial cartilage volume loss (p = 0.02) and
increased medial tibiofemoral cartilage defect severity (p = 0.04).
Conclusions: The results of this study suggest that markers of cartilage
metabolism either individually or as a ratio, may be used to identify OA
patients who are likely to suffer a loss of cartilage volume or increase in
cartilage defect as deﬁned by MRI and in the longer-term require joint
replacement. Providing appropriate treatment to this patient group may
with time reduce the overall burden of this disease.
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Purpose: Antigenic keratan sulfate (agKS) and hyaluronic acid (HA)
have each been studied as putative biomarkers to assess joint disease.
Whereas agKS in serum is thought to reﬂect cartilage metabolism, HA
is generally related to systemic inﬂammation. As part of a long-term
controlled trial of the biomechanical effects of wedged orthotic shoe
inserts in medial compartment OA, biomarkers were monitored. Here,
we assess the relationship of agKS and HA in serum to structural
progression, using radiographic joint space narrowing (JSN) as a marker
of progression.
Methods: 100 subjects (Kellgren-Lawrence grade 2−3, pain on ambu-
lation >30mm on a 100mm visual analog scale) were enrolled into a
36 month randomized controlled trial of orthotic wedges vs neutral orthotic
inserts in medial knee OA. Serum for biomarkers was analyzed in 47
randomly selected subjects, 27 from the wedge group and 20 from the
neutral group; 16 were males, 31 were females, mean age 59±10 years.
Subjects underwent semi-ﬂexed ﬂuoroscopic-guided PA knee radiography
(Schuss view) at entry and at 36 months, and the medial compartment
JSWs were quantiﬁed using Image J software (US NIH, Bethesda, MD,
http://rsb.info.nih.gov/ij/). Serum levels of baseline and 12-month agKS
and HA were determined by ELISA. p< 0.05 was considered signiﬁcant
in the statistical analysis.
Results: Baseline levels did not differ between the wedge and the neu-
tral orthotics groups for either HA (48.67±28.91 vs 68.15±56.56 ng/ml,
respectively, t-test p = 0.13, respectively) or agKS (363.22±129.60 vs
360.60±125.08, t-test p = 0.95), nor was there signiﬁcant change at 12
mos for either group (p> 0.05 for all variables). The medial compart-
ment JSW of the index knees at baseline in the wedge and control
groups were 3.22±1.58 and 3.32±1.72mm, respectively (p = 0.76), and at
36 months, the decline in JSWs were −0.057±1.13 and 0.271±0.427mm,
respectively (p = 0.31). Of the 47 patients who had baseline serum levels
determined, 32 patients completed the 36-month study and were included
in the correlation analyses. Although group biomarker differences were
not signiﬁcant, the baseline serum agKS level was signiﬁcantly negatively
correlated with the rate of joint space narrowing (JSN) over 36 months
(Pearson’s r = −0.41, p = 0.021). Similarly, the change in agKS during the
ﬁrst 12 months was negatively correlated with JSN (Pearson’s r = −0.40,
p = 0.033). In contrast, neither the baseline HA level nor the change in
HA during 12 months correlated with the rate of JSN (r = −0.13, p = 0.5
and r = 0.056, p = 0.97, respectively).
Conclusions: These data suggest that the structural progression in OA is
unrelated to HA levels, which may imply that the inﬂammatory component
in OA is less important to progression of JSN than in the systemic
inﬂammatory diseases. However, structural progression in OA appears
to be negatively related to serum agKS. As agKS is considered a marker
of cartilage metabolism, the ﬁnding of a negative relationship between
agKS levels (and change over time) with OA structural progression may
suggest that individuals with more metabolically active cartilage are better
able to resist the degenerative processes of OA.
105 A NOVEL MODEL SYSTEM FOR DRUG DISCOVERY
IN OSTEOARTHRITIS: MONITORING WHOLE TISSUE
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Purpose: The pathophysiology of osteoarthritis (OA) comprises the
whole joint. OA is characterized by chondrocyte hypertrophy, cartilage
degradation and altered subchondral bone resulting from changes in
osteoclastic bone resorption and osteoblastic bone formation. At present
there are neither biological models nor tools that allow investigation of the
interactions between osteoblasts, osteoclasts and chondrocytes. Thus,
we developed a femur head model, which will allow for investigate whole
tissue pathology. This will aid to identify novel molecules and targets,
which will affect the whole joint, as thereby hopefully identify candidates
for drug development within osteoarthritis.
Methods: Femur heads from three week old mice were isolated and
cultured for 10 days in DMEM:F12 containing IGF-I [100 nM], PTH
[100 nM], RANKL [100 ng/ml], Il-1a [10 ng/ml], OSM [10 ng/ml] + TNF-a
[20 ng/ml], OSM [10 ng/ml] + TNF-a [20 ng/ml] + GM6001 [10mM] and
GM6001 [10mM] alone. The conditioned medium was kept for analy-
sis of biochemical markers of bone and cartilage turnover, including
CTX-I (bone resorption), CTX-II (cartilage degradation), PIINP (cartilage
